La Roche-Posay Mela B3 SPF 30 Anti-Dark Spots Corrective Protective Care 40ml

  • Dark Spot Correction
  • UV Protection
  • Tone Evening
$ 50.42 USD $ 39.60 USD

Estimated delivery between September 03 and September 05. Order within .

La Roche-Posay Mela B3 Anti-Dark Spots Moisturiser SPF 30 is a dermatologist-developed, lightweight daily moisturizer with broad-spectrum SPF 30 protection that corrects and prevents dark spots, hyperpigmentation, and uneven tone while shielding against UVA/UVB rays to reduce sun-induced discoloration and aging signs, suitable for all skin tones and types including sensitive skin. It harnesses the innovative Melasyl™ (a multi-patented exclusive ingredient developed after years of research) to target and reduce persistent dark spots by neutralizing melanin precursors for long-lasting correction, combined with Niacinamide (Vitamin B3) to brighten, even tone, strengthen the skin barrier, and minimize inflammation, plus hydrating Glycerin and soothing La Roche-Posay Thermal Spring Water for comfort and radiance without greasiness.

  • Corrects & fades dark spots effectively.
  • SPF 30 broad-spectrum UV protection.
  • Brightens & evens skin tone.
  • Prevents new pigmentation recurrence.
  • Lightweight, non-greasy daily moisturizer.
  • Melasyl™
  • Niacinamide
  • Apply La Roche-Posay Mela B3 Anti-Dark Spots Moisturiser SPF 30 evenly to clean face and neck as part of your morning skincare routine; massage gently until absorbed; avoid direct contact with eyes; reapply as needed during sun exposure for continued protection.
  • La Roche-Posay Laboratoire Dermatologique

Avenue Rene Levayer La Roche-Posay, 86270 France.

Pay with

  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Klarna
  • Maestro
  • Mastercard
  • Shop Pay
  • Union Pay
  • Visa

Your transaction is protected with advanced security measures to keep your information confidential

$ 50.42 USD $ 39.60 USD

Worldwide Shipping

Free Shipment Above $150

100% Genuine Products

Dermatologist Approved